ORFLO is announcing a collaboration with the University of Pennsylvania (Penn) to evaluate the use of the ORFLO Moxi Go II during the manufacturing of CART cells.
The Moxi Go II combines two cell analysis QC tools in one; Coulter Principle single cell count and cell volume analysis with two channels of flow cytometry. Additionally, the Moxi Go II utilizes a disposable flow cell eliminating the need to clean or maintain the instrument. It also provides a near real-time quantitative count, cell volume, viability result (20 seconds) with a simultaneous enumeration of CD8 (or other markers), using a small sample volume (15uls). The instrument is compact enabling researchers to deploy the system at their point of T-cell expansion and incorporates simple “touch-and-go” apps. Ultimately the goal is to greatly improve downstream results and research efficiencies by combining these measurements into one highly accurate test.
“We are pleased to partner with Dr. Ruella and Penn Medicine, both pioneers in the field of immunotherapy research and development, to explore a new T-cell expansion monitoring solution that we hope will play a role in future research advances in this field,” said Don O’Neil, ORFLO’s SVP.
About ORFLO
ORFLO (www.orflo.com) is a life sciences company developing and marketing revolutionary instrumentation protein and cell analysis. At the core of ORFLO’s instrumentation is a patent protected disposable, micro-fluidic, electronic optic flow cell. ORFLO’s instruments provide a powerful unique window to cell analysis by directly measuring fluorescence and cell volume simultaneously. This coupled with the industry leading ease of use, affordability and elimination of maintenance will enable a significant increase in the pace of discovery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180724005845/en/
Source: ORFLO Technologies
View this news release online at:
http://www.businesswire.com/news/home/20180724005845/en
